Therapeutic efficacy, safety and gametocyte clearance after antimalarial treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Northeast Ethiopia Authors: Habtu Debash, Mihret Tilahun, Sisay Desale, Emiyamrew Getnet, Abdurehman Eshete Mohammed Published: 2026 ABSTRACT AbstractMalaria remains a major public health challenge in Ethiopia, with Plasmodium falciparum and Plasmodium vivax accounting for most malaria cases. Continuous monitoring of antimalarial drug efficacy and safety is essential to ensure effective case management and to detect early signs of emerging drug resistance. In addition, understanding gametocyte clearance following treatment is important because persistent gametocytaemia can sustain malaria transmission. This study assessed the therapeutic efficacy, safety, and gametocyte clearance following antimalarial treatment among patients with uncomplicated P. falciparum and P. vivax malaria in Northeast Ethiopia. A prospective observational study was conducted from November 2024 to January 2026 among 159 patients with uncomplicated malaria, including 81 P. falciparum and 78 P. vivax infections. Patients received treatment according to national guidelines, with artemether-lumefantrine for P. falciparum and chloroquine for P. vivax, while a subset also received a single low dose of primaquine. Participants were followed for 28 days to assess therapeutic outcomes, fever clearance, asexual parasite clearance, haemoglobin recovery, gametocyte clearance and adverse events. Data were analysed using SPSS version 26.0. Kaplan-Meier survival analysis was used to evaluate fever, parasite, and gametocyte clearance. Statistical significance was considered at p < 0.05. Therapeutic efficacy was high in both species, with adequate clinical and parasitological response rates of 88.9% among P. falciparum patients and 97.4% among P. vivax patients. Fever and asexual parasite clearance occurred more rapidly in P. vivax than in P. falciparum, with median fever clearance times of 2 and 3 days and median parasite clearance times of 2 and 4 days, respectively. Haemoglobin levels improved throughout follow-up in both groups, although P. falciparum infections were associated with lower baseline haemoglobin levels. Antimalarial treatments were generally well tolerated, with most adverse events being mild and no treatment discontinuations recorded. A transient increase in gametocyte carriage on day 3 was observed more frequently among participants who did not receive primaquine. Primaquine significantly accelerated gametocyte clearance, reducing the median clearance time from 11 to 7 days in P. falciparum and from 7 to 4 days in P. vivax. Higher baseline gametocyte density was associated with slower gametocyte clearance, particularly among P. falciparum patients. First-line antimalarial treatments remain highly effective and well tolerated for the management of uncomplicated P. falciparum and P. vivax malaria in Northeast Ethiopia. However, post-treatment gametocyte persistence may contribute to ongoing transmission, particularly in P. falciparum infections. The addition of low-dose primaquine significantly enhanced gametocyte clearance in both species, highlighting its potential role in reducing transmission and supporting malaria elimination efforts.Keywords: Malaria, Therapeutic efficacy, Safety, Gametocyte clearance, EthiopiaSubject terms: Diseases, Medical research, Microbiology Introduction Malaria remains a major public health challenge caused by Plasmodium parasites transmitted through the bites of infected female Anopheles mosquitoes1. Despite substantial progress in prevention and control, malaria continues to impose a considerable burden on public health, particularly in low- and middle-income countries. According to the World Health Organization (WHO), an estimated 282 million malaria cases and 610,000 deaths occurred globally in 2024, with the WHO African Region accounting for the overwhelming majority of infections and deaths1. Beyond its health consequences, malaria contributes to substantial economic losses through reduced productivity, increased healthcare costs and adverse effects on educational attainment and community development2,3. Ethiopia remains one of the malaria-endemic countries in sub-Saharan Africa, with nearly three-quarters of its land area suitable for transmission and more than 60 million people at risk of infection. Plasmodium falciparum and Plasmodium vivax are the dominant malaria species and together account for almost all reported cases in the country1. To reduce malaria morbidity and mortality, Ethiopia has implemented a range of interventions, including vector control, parasitological diagnosis and prompt treatment of confirmed cases. Artemisinin-based combination therapies (ACTs), particularly artemether–lumefantrine, are recommended as first-line treatment for uncomplicated P. falciparum malaria, while chloroquine remains the standard treatment for uncomplicated P. vivax malaria in most parts of the country1,4,5. The continued effectiveness of these medicines is critical for sustaining progress towards malaria elimination. Regular monitoring of antimalarial therapeutic efficacy is a cornerstone of malaria control and elimination programmes. Therapeutic efficacy studies provide essential evidence on treatment performance under field conditions and serve as an early warning system for the emergence and spread of antimalarial drug resistance1,6. Although ACTs remain highly effective in many malaria-endemic settings, the emergence of partial artemisinin resistance associated with mutations in the kelch13 gene has raised concerns about the long-term effectiveness of current treatment strategies7,8. Similarly, reports of reduced chloroquine susceptibility in P. vivax from several endemic regions highlight the importance of continued surveillance to ensure that recommended therapies maintain acceptable levels of efficacy9,10. In this context, periodic evaluation of treatment outcomes remains essential for guiding evidence-based malaria treatment policies. In addition to clearing asexual blood-stage parasites and resolving clinical symptoms, effective antimalarial treatment should reduce the potential for onward transmission. This is largely determined by its impact on gametocytes, the sexual stages of the parasite that are responsible for infecting mosquitoes. While ACTs rapidly eliminate asexual parasites and immature gametocytes, mature gametocytes may persist following treatment, allowing infected individuals to remain infectious even after clinical recovery7,11,12. Furthermore, post-treatment increases in gametocyte carriage have occasionally been observed and may reflect complex interactions among parasite biology, host immunity, and drug action7,13. The duration and magnitude of gametocyte carriage therefore provide valuable information on the transmission-reducing potential of antimalarial medicines and may offer additional insights into emerging changes in parasite susceptibility11–13. Assessment of treatment safety is equally important when evaluating antimalarial medicines. Although ACTs and chloroquine are generally well tolerated, adverse events can influence treatment adherence, patient acceptance, and overall treatment effectiveness. Monitoring the frequency, severity, and nature of adverse events is therefore essential to ensure that recommended therapies remain both safe and effective for routine clinical use and to support evidence-based treatment policy decisions1,14. Comprehensive evaluation of therapeutic efficacy, safety and gametocyte dynamics provides a more complete understanding of treatment performance and informs malaria control and elimination strategies15. Despite ongoing malaria control efforts in Ethiopia, evidence on therapeutic efficacy, safety and post-treatment gametocyte dynamics remains limited in many endemic areas, particularly in Northeast Ethiopia where both P. falciparum and P. vivax co-exist. Most therapeutic efficacy studies conducted in the country have focused primarily on parasite and fever clearance, with comparatively less attention given to gametocyte clearance and treatment-related adverse events. As Ethiopia advances towards malaria elimination, understanding the broader impact of antimalarial treatment on both clinical outcomes and transmission potential has become increasingly important. Therefore, this study aimed to evaluate the therapeutic efficacy, safety profile and gametocyte clearance following antimalarial treatment among patients with uncomplicated P. falciparum and P. vivax malaria in Northeast Ethiopia. The findings will generate locally relevant evidence to inform treatment policy, strengthen antimalarial drug efficacy surveillance, facilitate early detection of emerging drug resistance, and contribute to national malaria control and elimination efforts in Ethiopia. Materials and methods Study area The study was conducted in Kombolcha General Hospital, Kemissie General Hospital and Kemissie Health Center. Kombolcha General Hospital is found in South Wollo Zone, while Kemissie General Hospital and Kemissie Health Center are found in Oromia Special Zone, Amhara Regional State, Northeast Ethiopia. The study areas are malaria endemic areas in which both Plasmodium falciparum and Plasmodium vivax are highly prevalent. Kombolcha (11° 07′ N, 39° 43′ E) is 1875 m above sea level and 376 km northeast of Addis Ababa, which is the capital city of Ethiopia. On the other hand, Oromia Special Zone is 224 km mnortheast of Addis Ababa and has a latitude and longitude of 10°43′N 39°52′E with an elevation of 1424 m above sea level. The areas receive high rainfall during the main rainy seasons (June to September). The study areas are characterized by markedly unstable seasonal malaria. Malaria was one of the top ten diseases in the outpatients of those health facilities and reported throughout the year16. Study design and period A one-arm, prospective observational study was conducted to evaluate the therapeutic efficacy and safety of directly observed antimalarial treatment in patients with uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. The study followed patients to assess important clinical and parasitological outcomes, including fever resolution, asexual parasite clearance, haemoglobin recovery, changes in gametocyte carriage, and the occurrence of any treatment-related adverse events. The study was carried out from November 2024 to January 2026. Source and study population The source population included all patients diagnosed with P. falciparum or P. vivax malaria who attended Kombolcha hospital, Kemissie hospital and Kemissie health center during the study period. From this group, the study population comprised patients with microscopically confirmed P. falciparum or P. vivax mono-infection who presented to the selected hospitals within the study period and fulfilled the predefined eligibility criteria. Inclusion criteria. Patients aged ≥ 6 months with microscopically confirmed uncomplicated P. falciparum or P. vivax mono-infection were eligible for enrolment if they had detectable sexual parasitaemia, an asexual parasite density > 250 parasites/µL of blood, and a body weight ≥ 5 kg. Eligible participants were required to reside within the catchment area of the participating health facilities and to present with an axillary temperature > 37.5 °C or a history of fever within the preceding 48 h. Female participants were included only if they were neither pregnant nor breastfeeding. Written informed consent was obtained from adult participants or from parents/guardians of children prior to enrolment. In addition, participants had to be willing and able to comply with study procedures and attend all scheduled follow-up visits. Patients fulfilling these criteria, as well as the World Health Organization eligibility requirements for therapeutic efficacy studies, were enrolled in the study6. Exclusion criteria Patients with mixed-species malaria infections or malaria due to non-P. falciparum or non-P. vivax species were excluded from the study. Patients presenting with febrile illnesses of non-malarial origin, known chronic or severe underlying medical conditions, or severe malnutrition as defined by WHO criteria were also excluded. Additional exclusion criteria included a history of hypersensitivity to the study medications, haemoglobin level < 5.0 g/dL, inability to tolerate oral antimalarial therapy, or persistent vomiting. Patients who had received antimalarial treatment within the preceding two weeks or who were taking medications with potential to interfere with the pharmacokinetics of the study drugs were likewise excluded6. Sample size and sampling method World Health Organization 2010 guideline, method for the surveillance of antimalarial drug efficacy was used as a reference standard. Sample size was determined by using the single population proportion formula and assuming a 5% margin of error, 95% confidence interval (CI), treatment failure of 5%, and an additional 20% loss to follow-up rate and withdrawal of consent6. The sample size will be 75 + 15= 90. Accordingly, 90 study participants for each plasmodium species (90 = P. falciparum and 90 = P. vivax) with a total of 180 participants was enrolled in the study. For this study Kombolcha hospital, Kemissie hospital and Kemissie health center were selected purposively due to the number of malaria cases. Proportional allocation of sample sizes was done for each health facilities based on the previous similar months of data collection period. Accordingly, 56, 73 and 51 malaria infected patients were included from Kombolcha hospital, Kemissie Hospital and Kemissie health center, respectively. Finally, purposive sampling technique was employed to recruit participants. Dependent and independent variables The dependent variables included treatment outcomes, specifically adequate clinical and parasitological response (ACPR), early treatment failure (ETF), late clinical failure (LCF), and late parasitological failure (LPF), as well as fever clearance time, asexual parasite clearance time, gametocyte dynamics (day-3 gametocyte changes), gametocyte clearance time, and the occurrence of adverse events. The independent variables comprised socio-demographic factors (age, sex, and residence), clinical factors (body temperature, haemoglobin level, and body weight), parasitological factors (baseline parasite density, baseline gametocyte density and malaria species), and treatment-related factors, particularly the use of primaquine. Data collection and laboratory methods Baseline evaluation and data collection Base-line physical and clinical examinations with particular attention to any danger signs or symptoms associated with severe malaria were thoroughly assessed by a clinician. Socio-demographic information from the study participants was collected and recorded on a standardized antimalarial efficacy case screening form6 by well-trained clinicians and senior laboratory technologists using questionnaires. A Patient who meets the selection criteria at this stage was assigned a patient identification number and referred to the laboratory again for further laboratory investigation and sample collection. Blood samples were collected by finger prick, and think and thin blood films were prepared. Gametocyte densities were quantified by microscopy by counting against 500 leukocytes in the thick smear converted to numbers of parasites per micro-litre by assuming a standard count of 800 leukocytes per micro-litre of blood after staining with 10% Giemsa stain. Moreover, the number of asexual stages of the parasites were counted against 200 WBCs and parasitemia was determined as: number of parasites per/µL = (Parasite count × 8,000 WBC) /(200WBC). Drug administration and treatment follow up Smears were prepared immediately prior to treatment initiation and after completion of treatment, the gametocyte densities were calculated to determine the gametocyte conversion rate. Study participants who were P. falciparum and P. vivax mono-infected patients were treated with standard dose of antimalarial drugs according to the national malaria treatment guideline. Patients were followed for 30 min for presence of vomiting, if vomiting occur, the patients were re-treated with the same full dose. The treated participants were followed for 28 days, on fixed schedule. Blood samples were collected via a finger prick and spotted on a slide from the study subjects and followed up on day 0, 3, 7, 14, 21 and 28 for microscopic examination. Parasitological and clinical assessment were done on day 0, 3, 7, 14, 21 and 28. On every visit, Giemsa-stained thin and thick blood smear were prepared by laboratory technologists, and both asexual and gametocyte densities were assessed simultaneously by counting against 200 leukocytes and 500 respectively. Samples were considered negative if no parasites were detected in 100 fields (10 × 100 magnification). Treatment outcomes of patients who completed 28 days follow-up were classified based on the parasitological and clinical findings as per the WHO protocol6. Quality assurance All collected data were cross-checked for completeness and consistency prior to analysis. All laboratory procedures were performed in accordance with standard operating procedures (SOPs). Giemsa stain was filtered before use to remove impurities, and fresh Giemsa working solution was prepared every six hours. Quality control slides were included throughout the study to ensure the accuracy and consistency of staining and microscopy results. In addition, a colour atlas of Plasmodium species was available at the laboratory bench to support accurate species identification. All blood smear slides were independently examined by two experienced laboratory technologists. In the event of discrepant findings, the slides were reviewed by a third experienced laboratory technologist, whose assessment served as the final result. Statistical analysis Data were entered and analysed using Statistical Package for Social Sciences (SPSS) version 26.0. Descriptive statistics were used to summarise baseline characteristics and study outcomes, including frequencies, percentages, means, standard deviations, medians, and interquartile ranges, as appropriate. Comparisons between Plasmodium falciparum and Plasmodium vivax groups were performed using the chi-square or Fisher’s exact test for categorical variables and independent t-tests or non-parametric equivalents for continuous variables, as appropriate, while fever clearance time, asexual parasite clearance time, and gametocyte clearance dynamics were analysed using Kaplan-Meier survival analysis, with group differences assessed using the log-rank test. In addition, Cox proportional hazards regression analysis was used to identify factors associated with gametocyte clearance, and results were presented as hazard ratios (HR) with 95% confidence intervals (CI), while multivariable Cox regression was applied to adjust for potential confounders. All statistical tests were two-tailed, and a p-value < 0.05 at a 95% confidence interval was considered statistically significant. Ethics approval and consent to participate The study protocol was reviewed and approved by the Ethical Review Committee of the College of Medicine and Health Sciences, Wollo University. Permission to conduct the study was also obtained from Kombolcha hospital, Kemissie hospital and Kemissie health center. Informed written consent was obtained from all adult participants, while assent was obtained from children through their parents or legal guardians. Throughout the study, strict confidentiality of participant information was maintained. Participants who tested positive for Plasmodium species were promptly managed and treated at the respective health facilities in line with the national standard treatment guidelines. All methods were carried out in accordance with the Declaration of Helsinki guidelines and regulations. Results Study population and baseline characteristics A total of 159 patients were enrolled, 81 with P. falciparum and 78 with P. vivax. The majority of patients were male (66.7%), people aged 15 and up (82.4%), rural dwellers (69.8%) and recruiting from Kemissie Hospital (41.5%). Mean body weight was comparable between groups, but baseline parasitological indicators were much higher in P. falciparum, with approximately twice the asexual parasite density and significantly higher gametocyte density than in P. vivax. All P. falciparum cases were treated with artemether-lumefantrine (AL), while P. vivax patients were treated with chloroquine (CQ). Moreover, primaquine was co-administered in 23.9% of participants, mostly for gametocyte clearance (Table 1). Table 1Socio-demographic and baseline clinical characteristics of study participants by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026.VariableAlternativesPlasmodium speciesTotal Number (%)P. falciparum Number (%)P. vivax Number (%)SexMale57 (70.4%)49 (62.8%)106 (66.7%)Female24 (29.6%)29 (37.2%)53 (33.3%)Name of health facilityKemissie Hospital36 (44.4%)30 (38.5%)66 (41.5%)Kemissie Health Center22 (27.2%)22 (28.2%)44 (27.7%)Kombolcha Hospital23 (28.4%)26 (33.3%)49 (30.8%)Age< 5 years3 (3.7%)1 (1.3%)4 (2.5%)5–14 years10 (12.3%)14 (17.9%)24 (15.1%)≥ 15 years68 (84.0%)63 (80.8%)131 (82.4%)ResidenceRural58 (71.6%)53 (67.9%)111 (69.8%)Urban23 (28.4%)25 (32.1%)48 (30.2%)Weight (kg)Mean ± SD54.8 ± 12.652.9 ± 13.153.9 ± 12.9Baseline asexual parasite density (/µL)Mean ± SD18,450 ± 9,8709,320 ± 5,41013,980 ± 8,940Baseline gametocyte density (/µL)Mean ± SD1,240 ± 680420 ± 210840 ± 590Primaquine received (%)Yes24 (15.1%)14 (8.8%)38 (23.9%)No57 (35.8%)64 (40.3%)121 (76.1%) Socio-demographic and baseline clinical characteristics of study participants by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Fever clearance Every patient had a fever at enrollment and during follow-up, the fever gradually subsided with P. vivax infections showing a quicker reduction. Although both groups had full defervescence by day 7, 87.2% of patients with P. vivax and 49.4% of those with P. falciparum were afebrile by day 2. Plasmodium vivax infections had a much shorter median fever clearance time (2 days, IQR 1–2) than P. falciparum infections (3 days, IQR 2–4). Kaplan-Meier survival analysis found a significant difference in fever resolution between species (log-rank p < 0.001). Cox proportional hazards modeling revealed that patients with P. vivax were 1.85 times more likely to achieve fever clearance at any given time compared to those with P. falciparum (HR = 1.85; 95% CI: 1.35–2.52; p < 0.001) (Table 2). Table 2Fever clearance by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026.P. falciparum infected patientsP. vivax infected patientsFever cleared n/NClearance rate (%)Fever cleared n/NClearance rate (%)Day 00/810%0/780%Day 124/8129.6%33/7842.3%Day 240/8149.4%68/7887.2%Day 363/8177.8%75/7896.2%Day 7–2881/81100%78/78100%Parameter P. falciparum P. vivax Comparison Statistical summary Median fever clearance (days)3 (IQR 2–4)2 (IQR 1–2)log-rank p < 0.00195% CI median2–41–2–Hazard Ratio (P. falciparum vs. P. vivax)––HR = 1.85 (95% CI: 1.35–2.52), p < 0.001 Fever clearance by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Hemoglobulin values at the baseline At enrollment, all subjects had uncomplicated malaria, and anaemia was more prominent in P. falciparum patients than in P. vivax. Mild anaemia was the most common overall presentation (40.9%), while moderate anaemia occurred significantly more frequently in P. falciparum (34.6%) than in P. vivax infections (12.8%). Severe anaemia was rare, occurring solely in P. falciparum cases (7.4%) with no cases recorded among P. vivax patients (Fig. 1). Comparative distribution of anaemia at baseline by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Haemoglobin changes over 28 days At baseline, patients with P. falciparum had significantly lower mean haemoglobin levels than those with P. vivax (10.8 ± 1.5 vs. 12.3 ± 1.1 g/dL; p < 0.001). During follow-up, hemoglobin concentrations gradually increased in both groups. Mean Hb levels in P. falciparum cases decreased somewhat by day 3 before steadily recovering until day 28 (10.1 to 12.3 g/dL), but P. vivax patients maintained consistently higher Hb levels throughout follow-up (11.9 to 13.5 g/dL). Inter-species differences were statistically significant at all time intervals (p < 0.001), indicating P. falciparum has a higher haematological impact even in uncomplicated malaria (Fig. 2). Haemoglobin changes over 28 follow-up days by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Asexual parasite clearance At the time of enrolment, all participants had parasitaemia in both P. falciparum and P. vivax infected patients. On day 3, parasite clearance was higher in P. vivax patients (92.3%) than in P. falciparum patients (85.2%), but the difference was not statistically significant (p = 0.12). However, Kaplan-Meier survival analysis revealed that parasite clearance in P. vivax infections was substantially faster with a median clearance time of 2 days (95% CI: 1–3) compared to 4 days (95% CI: 3–5) for P. falciparum. Patients with P. vivax were almost twice as likely to clear parasites at any given time point, according to Cox proportional hazards modelling (HR = 1.92; 95% CI: 1.38–2.68; log-rank p < 0.01). All patients had complete parasite elimination by day 14, showing the strong treatment effectiveness in uncomplicated malaria (Table 3). Table 3Asexual parasite clearance dynamics over 28 days by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026.Follow-up dayP. falciparum cleared n/N (%)P. vivax cleared n/N (%)P-value (between species)Day 00/81 (0%)0/78 (0%)-Day 369/81 (85.2%)72/78 (92.3%)0.12Day 780/81 (98.8%)78/78 (100%)0.31Day 14–2881/81 (100%)78/78 (100%)-Median clearance time (days)42Log-rank p < 0.0195% CI (days)3–51–3-Event (parasite-free)81/81 (100%)78/78 (100%)-Censored0/810/78-Hazard Ratio (Pv vs. Pf)Reference1.92 (95% CI: 1.38–2.68)- Asexual parasite clearance dynamics over 28 days by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Therapeutic outcomes Both Plasmodium species had high therapeutic efficacy with ACPR seen in 88.9% of P. falciparum cases and 97.4% of P. vivax cases. P. falciparum had somewhat higher rates of treatment failures (ETF, LCF, and LPF). Overall, these findings suggest that antimalarial medication is beneficial for simple infections with P. vivax performing slightly better (Fig. 3). Therapeutic outcomes by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Adverse events Standard antimalarial medications were generally well tolerated in patients with uncomplicated malaria. Most participants (92.5%) experienced no adverse effects or only mild, self-limiting symptoms during follow-up. Serious adverse events were observed in 2.55% of patients with Plasmodium falciparum infection. These included severe hypersensitivity or allergic reactions, severe cutaneous adverse reactions and severe gastrointestinal intolerance. Importantly, all patients completed their treatment and follow-up without interruption. No severe adverse effects were reported among patients with P. vivax infection (Fig. 4). Adverse events by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Post-treatment day-3 gametocyte boost All participants were positive for both asexual parasites and gametocytes at enrolment. By Day 3, a transient increase in gametocyte carriage was observed following treatment. This temporary post-treatment rise was more common among patients who did not receive primaquine for both P. falciparum and P. vivax infections (Table 4). Overall, 17.6% (28/159) of participants experienced a transient increase in gametocytaemia on Day 3, indicating that primaquine may help reduce early post-treatment gametocyte carriage. Table 4Post-treatment day-3 gametocyte boost by Plasmodium species and primaquine use in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026.Plasmodium speciesPrimaquine useDay 3 boost (n/N)Boost rate (%)Risk ratio (No PQ vs. PQ)χ2 p-value (with in species)P. falciparum (n = 81)Yes (n = 24)2/248.3No (n = 57)14/5724.62.96< 0.05P. vivax (n = 78)Yes (n = 14)1/147.1No (n = 64)11/6417.22.41< 0.05Overall (n = 159)-28/15917.6-- Post-treatment day-3 gametocyte boost by Plasmodium species and primaquine use in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Gametocyte clearance of Plasmodium species In both P. falciparum and P. vivax infections, patients who received primaquine had considerably faster gametocyte clearance (log-rank p < 0.001). In P. falciparum, primaquine lowered median gametocyte clearance time from 11 to 7 days, while in P. vivax, it decreased it from 7 to 4. Primaquine-treated patients were more than three times more likely to remove gametocytes in P. falciparum and nearly three times more likely in P. vivax, demonstrating its significant effect on early gametocyte suppression (Table 5). Table 5Gametocyte clearance by Plasmodium species using Kaplan-Meier survival analysis in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026.Plasmodium speciesPrimaquine useMedian clearance time (days)95% CI (days)Hazard Ratio (PQ vs. No PQ)95% CI P. falciparum Yes76–83.22.1–4.8No119–12Reference- P. vivax Yes43–52.81.6–4.8No76–9Reference- Gametocyte clearance by Plasmodium species using Kaplan-Meier survival analysis in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Predictors of gametocyte clearance in P. falciparum and P. vivax Multivariable Cox regression analysis identified primaquine use as the strongest independent predictor of rapid gametocyte clearance in both P. falciparum (AHR = 3.4; p < 0.001) and P. vivax (AHR = 2.6; p < 0.001). Higher baseline gametocyte density significantly delayed clearance in P. falciparum, whereas in P. vivax it showed only a non-significant trend (Table 6). Table 6Multivariable Cox regression analysis of predictors of gametocyte clearance by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026.Variable P. falciparum P. vivax CategoryNumber (%)Adjusted HR (95% CI)p-valueCategoryNumber (%)Adjusted HR (95% CI)p-valuePrimaquine useYes24 (29.6%)3.4 (2.1–5.3)< 0.001Yes14 (17.9%)2.6 (1.6–4.1)< 0.001No57 (70.4%)1No64 (82.1%)1Baseline gametocytaemia> 500/µL77 (95.1%)0.68 (0.46–0.99)0.045> 500/µL54 (69.2%)0.72 (0.50–1.04)0.08≤ 500/µL4 (4.9%)1≤ 500/µL24 (30.8%)1Baseline parasitaemia> 10,000/µL80 (98.8%)0.81 (0.53–1.25)0.34> 10,000/µL60 (76.9%)0.89 (0.60–1.32)0.56≤ 10,000/µL1 (1.2%)1≤ 10,000/µL18 (23.1%)1Baseline haemoglobin< 11 g/dL45 (55.6%)0.92 (0.61–1.39)0.69< 11 g/dL10 (12.8%)0.88 (0.58–1.34)0.56≥ 11 g/dL36 (44.4%)1≥ 11 g/dL68 (87.2%)1Age group> 15 years68 (84.0%)1.08 (0.69–1.68)0.73> 15 years63 (80.8%)1.14 (0.74–1.76)0.54≤ 15 years13 (16.0%)1≤ 15 years15 (19.2%)1SexMale57 (70.4%)1.02 (0.67–1.56)0.93Male49 (62.8%)0.96 (0.63–1.46)0.84Female24 (29.6%)1Female29 (37.2%)1 Multivariable Cox regression analysis of predictors of gametocyte clearance by Plasmodium species in South Wollo and Oromia Special Zone Health Institutions, Northeast Ethiopia, 2026. Discussion Malaria continues to pose a major public health challenge in Ethiopia where P. falciparum and P. vivax cause significant febrile illness and anaemia. Although standard antimalarial therapies effectively clear asexual parasites, persistent gametocytes may continue to sustain transmission17,18. Importantly, patients with P. vivax recovered more quickly clinically and parasitologically than those infected with P. falciparum with earlier fever resolution and parasite clearance, which is likely due to biological differences such as lower parasite biomass and the absence of deep microvascular sequestration in P. vivax19–22. Consistently, higher baseline parasitaemia in P. falciparum infections was related with slower clearance dynamics and more severe clinical symptoms which is consistent with previous Ethiopian treatment efficacy studies14,15,20. Together, these observations underline the need for species-specific, transmission-focused strategies to sustain malaria control and support equitable elimination efforts in endemic communities. Anaemia was much more common in P. falciparum patients, with moderate to severe cases, whereas P. vivax infections were generally associated with mild anaemia. This pattern represents increased erythrocyte destruction and bone marrow suppression caused by enhanced P. falciparum parasitaemia23,24. In Ethiopia, where malaria episodes are common in seasonal transmission areas, the cumulative burden exacerbates anaemia25. During follow-up, haemoglobin levels gradually improved in both groups; P. vivax patients had higher levels throughout, whereas P. falciparum cases had an early post-treatment decline followed by steady recovery by day 28, consistent with acute haemolysis after parasite clearance and subsequent bone marrow regeneration26. These findings emphasize the importance of rigorous hemoglobin monitoring and supportive management, particularly in P. falciparum infections, to ensure a safe and complete clinical recovery. Parasite clearance dynamics further illustrate species-specific differences. All subjects had cleared asexual parasitaemia by day 14 with P. vivax infections resolving faster than P. falciparum, with a median clearance of 2 days (95% CI: 1–3) versus 4 days (95% CI: 3–5), indicating species-specific changes in parasite biology and therapeutic response. The rapid clearance of P. vivax is most likely due to its continued chloroquine susceptibility27,28, whereas the rapid reduction of parasite biomass in P. falciparum verifies artemether-lumefantrine’s long-term efficacy as Ethiopia’s first-line treatment14,29. Although microscopy revealed that most P. falciparum infections were cleared by day 3, molecular studies show that low-density submicroscopic parasitaemia can sometimes persist beyond conventional detection limits30. Both species demonstrated high therapeutic efficacy, with ACPR rates of 97.4% for P. vivax and 88.9% for P. falciparum, and adverse events were mostly mild or absent, indicating that these regimens are still safe and tolerable in endemic populations. These findings were comparable with studies done in different parts of Ethiopia14,15,27. Gametocyte dynamics provide additional insight into transmission risk. Patients with P. falciparum who did not receive primaquine showed a transient increase in gametocyte carriage on day 3, most likely due to the unmasking of mature gametocytes or the induction of sexual differentiation following asexual parasite clearance13,29. Conversely, a single low dose of primaquine added to artemisinin-based combination therapy accelerated gametocyte clearance, with gametocytes almost undetectable by day 7, demonstrating effective transmission-blocking without increasing adverse events11,31. In contrast, P. vivax gametocytes emerge early and are typically removed by normal chloroquine therapy, but primaquine is used in 7–14 days regimen to target liver-stage hypnozoites and avoid relapses. Rapid gametocyte clearance in P. falciparum is critical because even low-density gametocytemia can sustain transmission32. Multivariable analysis revealed that primaquine administration was the strongest and only significant predictor of gametocyte clearance in both P. falciparum and P. vivax, emphasizing its importance as a gametocytocidal agent in malaria transmission reduction12. Furthermore, higher baseline gametocyte densities in P. falciparum were related with delayed clearance, indicating that elevated sexual-stage parasite burdens prolong infectiousness and may sustain transmission if not removed rapidly32. These findings support WHO recommendations to add a single low dose of primaquine to standard artemisinin-based combination therapy in P. falciparum infections to rapidly eliminate gametocytes and reduce community-level malaria transmission, even in populations without prior G6PD testing17,18. Limitation of the study This study has some limitations that should be considered when interpreting the findings. The one-arm prospective observational design without randomization limits causal inference and introduces potential selection bias, particularly in evaluating the effect of primaquine. The relatively small sample size, particularly when analyzed by species and treatment groups, may have reduced the statistical power to detect modest differences. Gametocyte detection relied solely on light microscopy, which has limited sensitivity and may underestimate low-density or submicroscopic carriage, thereby underrepresenting true transmission potential. In addition, the absence of G6PD deficiency screening limits conclusions regarding the safety of primaquine. Conclusion and recommendations This study demonstrated that the current first-line antimalarial treatments remain highly effective for the treatment of uncomplicated P. falciparum and P. vivax malaria in Northeast Ethiopia. High adequate clinical and parasitological response rates were achieved in both species, with rapid fever resolution, complete asexual parasite clearance and steady improvement in haemoglobin levels throughout the follow-up period. The treatments were also generally safe and well tolerated, with most adverse events being mild and self-limiting and no treatment discontinuations recorded. Despite these encouraging outcomes, clear differences were observed between the two malaria species. Patients with P. falciparum infection presented with higher parasite and gametocyte densities, lower haemoglobin levels, slower fever and parasite clearance and longer persistence of gametocytes than those with P. vivax infection. Although overall treatment outcomes were favourable, a transient increase in gametocyte carriage was observed during the early post-treatment period, particularly among patients who did not receive primaquine. Importantly, the addition of a single low dose of primaquine substantially accelerated gametocyte clearance in both species, while higher baseline gametocyte density was associated with slower clearance, especially among patients with P. falciparum malaria. The findings support the continued use of the current first-line antimalarial regimens for the treatment of uncomplicated malaria in Ethiopia. Ongoing therapeutic efficacy surveillance should be strengthened to ensure that these drugs remain effective and to enable the timely detection of emerging drug resistance. Routine monitoring of treatment safety, haemoglobin recovery, and parasitological responses should also be maintained to support optimal patient care and programme performance. In line with national treatment guidelines, wider use of single low-dose primaquine alongside standard antimalarial therapy should be encouraged to enhance gametocyte clearance and reduce the potential for onward transmission. In addition, continued monitoring of post-treatment gametocyte carriage and further research incorporating molecular markers of drug resistance and transmission dynamics would provide valuable evidence to inform malaria control strategies and support Ethiopia’s progress towards malaria elimination. Acknowledgements The authors would like to thank Wollo University for financial support and giving ethical clearance and providing necessary materials. The authors also thank the study participants, data collectors, and Kemissie hospital, kemissie health center and Kombolcha hospital staffs for their support and unreserved cooperation in making this study to be a fruitful work. Author contributions H.D., M.T., S.D., E.G. and A.E.M. conceived and designed the study, prepared the proposal, supervised data collection, and analysed and interpreted the data. H.D. drafted the manuscript, and M.T., S.D., E.G. and A.E.M. critically reviewed it. All authors read and approved the final version of the manuscript and are accountable for all aspects of the work. Funding The research project was not funded by any organization. Data availability All data generated in this study are included in the manuscript. The data sets analysed during the current study are available from the corresponding author on reasonable request. Results Competing interest The authors declare no competing interest. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated in this study are included in the manuscript. The data sets analysed during the current study are available from the corresponding author on reasonable request.